The findings, derived from the Phase 3 Vivacity-MG3 study, highlight the drug's impact on patients regardless of their disease progression or baseline symptom severity. For individuals diagnosed within the last five years, IMAAVY combined with standard care showed a significant reduction in symptom scores compared to placebo, with more patients achieving sustained clinical improvement over 20 weeks. Similar benefits were observed in patients with lower initial symptom burdens, where the treatment improved daily functioning and severity scores.

Beyond efficacy, the data address critical clinical concerns, including the impact of common infections—a frequent trigger for disease exacerbations. Patients receiving the treatment maintained symptom control even after contracting infections, suggesting a resilient therapeutic effect. Furthermore, the company introduced the PETUNIA study, an initiative designed to fill existing evidence gaps regarding the drug’s safety profile during pregnancy. Researchers aim to leverage this study to provide clearer guidance for clinical decisions in populations where data has historically been limited.